During the 1-month IT due diligence at the beginning of the year, digatus subjected the target company’s IT landscape to a detailed review, including through:

• Analysis of the current IT situation
• Development of a potential IT vision
• Cost, investment and risk assessment
• Checking the compatibility and integration possibilities of applications

Infrareal Holding will take over the 24-hectare site, including the buildings, infrastructure facilities and some pharmaceutical production plants. The site in Orth, Austria, is a competence center for the pharmaceutical and life science industry with a focus on gene and cell therapy as well as biologics. Infrareal intends to use its many years of experience in the operation of pharmaceutical sites to expand and further develop the location. The company is thus pursuing its announced strategy of becoming one of the leading operators of pharmaceutical and biotech sites in the German-speaking region.

About Infrareal Holding GmbH & Co. KG
Infrareal employs over 800 people and specializes in the operation and development of pharmaceutical parks with a focus on pharmaceuticals, biotechnology and life sciences. To this end, it acquires new industrial parks, pharmaceutical parks, real estate and infrastructure in order to operate highly complex multi-user sites. It is particularly important to Infrareal to create long-term prospects for the respective locations. The company currently operates more than 250 buildings and facilities.